CD274 and melanoma: Consideration of expression of PD-L1 and TILs in low-m6Ascore group, we speculated that m6Ascore could predict the efficacy of PD-1/PD-L1 inhibitors, and patients with melanoma in low m6Ascore group were probably the optimal candidates for immunotherapy.